摘要
目的探讨奥氮平治疗精神分裂症的疗效和安全性。方法将60例精神分裂症患者随机分为研究组和对照组,每组各30例。研究组应用奥氮平治疗,起始剂量5mg·d-1,第2d增至10mg·d-1,最大剂量≤20mg·d-1;对照组应用氯氮平治疗,起始剂量50mg·d-1,1w内递增到300mg·d-1,最大剂量≤400mg·d-1。疗程均为8w。分别于治疗前及治疗第1、2、4、6、8w末采用阳性和阴性症状量表评定临床疗效,副反应量表评定不良反应。结果奥氮平有效率73.33%,氯氮平有效率76.66%;奥氮平在改善认知因子和阴性症状方面优于氯氮平,两组比较差异有显著性(P<0.05);奥氮平组主要不良反应有轻度头昏、瞌睡、体重增加等。结论奥氮平是一种安全有效的抗精神病药物,对改善认知功能和阴性症状效果显著。
Objectives To explore the curative effects and safety of olanzepine in the treatment of schizophrenia. Methods 60 schizophrenics were randomly divided into research (olanzepine, n=30) and controlled ( clozapine, n=30 ) groups . Initial dosage of olanzepine was 5mg/d , raised to 10mg/d on the 2nd day and the maximal was ≤20mg/d; initial dosage of clozapine was 50mg/d, raised to 300mg/d within one week and the maximal was≤400mg/d for 8 weeks. Curative effects were assessed with the Positive and Negative Symptom Scale (PANSS) and side effects with the Treatment Emergent Symptom Scale(TESS) before treatment and at the ends of week 1,2,4,6 and 8, respectively. Results The rates of olanzepine and clozapine were 73.33% and 76.66% respectively; olanzepine was better than clozapine in improving cognitive factor and negative symptoms, the difference was significant(P<0.05); The main side effects of olanzepine were mild dizziness, drowsiness, weight gain etc. Conclusion Olanzepine is an effective and safe neuroleptic, especially effectively improves cognitive function and negative symptoms.
出处
《临床心身疾病杂志》
CAS
2005年第3期217-218,共2页
Journal of Clinical Psychosomatic Diseases
